Regulation - The real threat to clinical research

BMJ

Volumn 337, Issue 7678, 2008, Pages 1085-1087

  Stewart, Paul ^a   Stears, Anna ^b   Tomlinson, Jeremy W ^c   Brown, Morris J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; ANTIHYPERTENSIVE AGENT; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBENOXOLONE; PLACEBO; THIAZIDE DIURETIC AGENT;

CLINICAL RESEARCH; CLINICAL TRIAL; DRUG APPROVAL; DRUG INDUSTRY; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MEDICAL ETHICS; OBESITY; PRIORITY JOURNAL; SHORT SURVEY; UNITED KINGDOM;

EID: 56549102160     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (15)

1. Smith R. UK is losing market share in pharmaceutical research. BMJ 2000; 321: 1041.
2. Big drug companies shift trials overseas. Financial Times 2008 June 26:3.
3. Hood SJ, Taylor KP, Ashby MJ, Brown MJ.The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossovertrial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 2007;116:268-75.
4. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006;48:219-24.
5. Tomlinson JW, Sherlock;M, Hughes B, Hughes SV, Kilvington F, Bartlett W, et al. Inhibition of 11-HSD1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol Metab 2007;92:857-64.
6. Directive 2001/20/EC of the European parliament and of the Council. www.eortc.org/Services/Doc/clinical-EUdirective-04-April-01.pdf.
7. Statutory Instrument 2004 No 1031. The medicines for human use (clinical trials) regulations.wwm.opsi.gov.uk/ si/si2004/20041031.htm.
8. Jamrozik K. Research ethics paperwork: what is the plot we seem to have lost? BMJ 2004;329:286-7.
9. Elwyn G, Seagrove A, Thome K, Cheung WY. Ethics and research governance in a multicentre study: add 150 days to your study protocol. BMJ 2005;330:847.
10. Robinson L, Murdoch-Eaton D, Carter Y. NHS research ethics committees. BMJ 2007;335:6.
11. National Institute for Health Research. Bureaucracy busting: NIHR coordinated system for gaining NHS permission. 2008. www.nihr.ac.uk/files/ pdfs/ lmplementation_Plan_4.1c_Central_sign_on_ April_2008.pdf.
12. Mitchell P. Critics pan timid European response to TeGenero disaster. NatBiotech 2007;25:485-6.
13. CenterWatch. Why people participate. wwwcenterwatchcom/patient/ ifcn_02html.
14. Office for Strategic Coordination of Health Research. Background on the review of health research in the UK and OSCHR. wwwnihracuk/ about_oschraspx. 2008.
15. Christie DR, Gabriel GS, Dear K. Adverse effects of a multicentre system for ethics approval on the progress of a prospective multicentre trial of cancer treatment: how many patients die waiting? Intern Med J 2007;37:680-6.